AI drug discovery
A model that reads the genome one cell at a time
Arc Institute's Bolero turns years of cell atlases from a catalog into something you can question.

Efthymios Vogiatzis · · 2 min read
Arc Institute, with Michael Greenberg's lab at Harvard Medical School, posted a model this week called Bolero.
Give it a stretch of DNA and a representation of which cell you mean, and it predicts how active the genes are and how open the DNA is in that specific cell type. It can even estimate what a sequence would do in a cell state nobody has profiled yet.
It shipped with its own training data: an atlas of 10.8 million cells, spanning human brain and body, across development and aging, and across species.
This is a preprint, so it hasn't been peer reviewed. The behavioral experiments could only run in model organisms, so the reads on human brain tissue lean on cross-species transfer. The authors are careful about that.
For years the field has been building cell atlases. The Human Cell Atlas, single-cell sequencing, map after map of which cells exist and what they're doing. Building the atlas was the triumph. Reading it, asking what a given piece of DNA actually does in this cell and not that one, stayed slow and manual.
A model that reads regulation per cell state is the tool that turns those atlases from a catalog into something you can question. The maps were step one. This is what they were for.
Sources
- Arc Institutehttps://arcinstitute.org/news/bolero
- bioRxiv preprint (not yet peer reviewed)https://www.biorxiv.org/content/10.64898/2026.10.19.760026v1
- Note: fresh preprint; no independent newsroom coverage located at time of writing.

Efthymios Vogiatzis
Efthymios Vogiatzis is a pharmacist turned AI and data product leader, and the founder of VE1 Advisory in Vienna. He has led AI, data and analytics work across life sciences, biopharmaceuticals, insurance and industrial technology.
Start a conversationField notes by email.
A new essay about once a month on AI, data integrity and the people side of change.
Keep reading
21 October 2026 · Operations · 2 min read
The quiet half of biotech: scaling it next to a sugar mill
A Brevel and Wave Group plant jumps from a 5,000-litre tank to 300,000 litres, on a feedstock sitting next door. Scale-up is the half that decides whether biology reaches a shelf.
September 2026 · AI drug discovery · LinkedIn
What a pharmacist sees in the AI pipeline
The habits that keep data honest when the model moves faster than the audit trail.
